FlowCam - Flow Imaging Microscopy Blog

Therapeutic Proteins Can Save Lives: Nano-Flow Imaging Helps Make These Drugs Safer

The positive impacts of therapeutic proteins on the lives of people suffering from cancer, diabetes, multiple sclerosis, Crohn’s disease, ALS, lupus, arthritis and other diseases and conditions have attracted significant investment in drug research and development.

As a result, hundreds of therapeutic protein-based drugs have earned FDA approval, with enormous benefits to human health. With the rapid growth and acceptance of these biologics, more and more information about impacts of product quality on patient outcomes has become available. Based on this growing body of evidence, one of the most important product quality attributes is the concentration and sizes of subvisible particles.

"Lives are on the line when it comes to correct understanding of how therapeutic proteins can form particulate" says Professor John Carpenter, PhD, Professor of  Pharmaceutical Sciences and Co-Director of the Center for Pharmaceutical Biotechnology at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences.

Read the entire article in Laboratory News

Click the infographic on the right to view larger

Read More

Topics: Protein Therapeutics, Biopharmaceutical Research, Nanoparticles

The Importance of Correct Aperture Settings in Nano Flow-Imaging

In microscope systems, it's the numerical aperture (NA) and the wavelength of the light that determine the minimum distance that two particles can be resolved. Clear images, accurate sizing, and consistent categorization all depend on your NA setting.

Read More

Topics: FlowCam Technology, Nanoparticles

We are attending the European Workshop on Protein Aggregation and Immunogenicity

The 4th Annual European Workshop on Protein Aggregation and Immunogenicity will be held in Salzburg-Wals, Austria on January 28 and 29.  This conference serves as a European summit for thought leaders and academic researchers to come together and discuss the issues of protein aggregation and its effects on the immunogenicity of therapeutic protein drug products. We are excited to attend and exhibit the FlowCam imaging particle analyzer with our German distributor, Anasysta.

Proteins and contaminants from a parenteral drug sample, imaged and analyzed by the FlowCam.

Read More

Topics: News and Events, Biopharmaceutical Research, Nanoparticles

New High-Throughput Method for Elastin-like Polymer (ELP) Coacervate Analysis

December 2018 — A recent study by researchers from the University of New England and University of New Hampshire has demonstrated that flow imaging microscopy is an accurate, more efficient, and more informative method of elastin-like polymer (ELP) coacervate analysis than standard methods. ELP coacervates are a class of molecules with promising applications in drug delivery vehicles, tissue engineering, environmental remediation, and more. ELP coacervate architecture is stimuli-responsive and highly tunable, making them ideal for the above-mentioned applications.  


Read More

Topics: Industrial Applications, User Spotlight, Biopharmaceutical Research, Nanoparticles

Top 5 Influential FlowCam Papers for Biopharma

FlowCam_8100 w no backgroundThe FlowCam continues to be an important instrument in biopharmaceutical research. The ability to image and characterize morphological features of particulate in parenteral formulations is an important aspect of ensuring quality and safety in injectable drug products.

Read More

Topics: Protein Therapeutics, FlowCam Technology, Biopharmaceutical Research, Nanoparticles

Detection of Subvisible Particulates in Bioformulations to Ensure Safety

NIST protein standards imaged on the FlowCam Nano at 40XBiopharmaceutical manufacturers strive to ensure patient safety, avoid recalls and protect company reputations. Identifying subvisible particles is an important step in preventing recalls of parenterals. One aspect of product safety is defined in the United States Pharmacopeia (USP) 788 guidelines for particle sizing.  This was designed to control for particles capable of causing capillary occlusion, and therefore focuses on particles larger than 10 µm and 25 µm. As such, no characterization is required for particles below 10 µm. 

Read More

Topics: Protein Therapeutics, Biopharmaceutical Research, Nanoparticles

FlowCam Nano Earns Pharma Innovation Award

We are proud to announce that our FlowCam Nano has earned the Pharmaceutical Manufacturing 2018 Pharma Innovation Award.  Honored in the category of Analytical and Monitoring Devices, the FlowCam Nano particle analyzer is recognized as the industry's first ever flow imaging nano particle analyzer that provides digital images of particles ranging in size from 300 nm to 10+ µm.

Read More

Topics: News and Events, Biopharmaceutical Research, Nanoparticles

Sub-visible dangers of plastic; nanoparticles in biopharmaceutical devices

Over the years, Fluid Imaging Technologies CEO, Kent Peterson has observed a shift in focus of process components in biopharmaceutical manufacturing from steel and glass to plastic (Single Use Technologies or SUT).  For sure there are advantages and disadvantages of each, from cost to breakage, to formulation interaction and stability.

Read More

Topics: Protein Therapeutics, Biopharmaceutical Research, Nanoparticles